SI3021873T1 - Sestavek za zdravljenje vnetne sklepne bolezni - Google Patents

Sestavek za zdravljenje vnetne sklepne bolezni

Info

Publication number
SI3021873T1
SI3021873T1 SI201430972T SI201430972T SI3021873T1 SI 3021873 T1 SI3021873 T1 SI 3021873T1 SI 201430972 T SI201430972 T SI 201430972T SI 201430972 T SI201430972 T SI 201430972T SI 3021873 T1 SI3021873 T1 SI 3021873T1
Authority
SI
Slovenia
Prior art keywords
treatment
composition
joint disease
inflammatory joint
inflammatory
Prior art date
Application number
SI201430972T
Other languages
English (en)
Inventor
Raymond A. Chavez
Linda R. Watkins
Robert Landry
Original Assignee
Xalud Therapeutics, Inc.
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xalud Therapeutics, Inc., The Regents Of The University Of Colorado, A Body Corporate filed Critical Xalud Therapeutics, Inc.
Publication of SI3021873T1 publication Critical patent/SI3021873T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Manufacturing & Machinery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201430972T 2013-07-18 2014-07-17 Sestavek za zdravljenje vnetne sklepne bolezni SI3021873T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847851P 2013-07-18 2013-07-18
PCT/US2014/047071 WO2015009955A1 (en) 2013-07-18 2014-07-17 Methods for the treatment of inflammatory joint disease
EP14826787.5A EP3021873B8 (en) 2013-07-18 2014-07-17 Composition for the treatment of inflammatory joint disease

Publications (1)

Publication Number Publication Date
SI3021873T1 true SI3021873T1 (sl) 2018-12-31

Family

ID=52346725

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201430972T SI3021873T1 (sl) 2013-07-18 2014-07-17 Sestavek za zdravljenje vnetne sklepne bolezni
SI201431402T SI3369435T1 (sl) 2013-07-18 2014-07-17 Sestavek za zdravljenje vnetne bolezni sklepov

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201431402T SI3369435T1 (sl) 2013-07-18 2014-07-17 Sestavek za zdravljenje vnetne bolezni sklepov

Country Status (14)

Country Link
US (4) US10512672B2 (sl)
EP (2) EP3369435B1 (sl)
JP (3) JP2016525522A (sl)
CY (2) CY1120946T1 (sl)
DK (2) DK3369435T3 (sl)
ES (2) ES2760902T3 (sl)
HR (2) HRP20181913T1 (sl)
HU (2) HUE046944T2 (sl)
LT (2) LT3369435T (sl)
PL (2) PL3021873T3 (sl)
PT (2) PT3369435T (sl)
RS (2) RS59735B1 (sl)
SI (2) SI3021873T1 (sl)
WO (1) WO2015009955A1 (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3369435T3 (da) 2013-07-18 2019-11-25 Xalud Therapeutics Inc Sammensætning til behandling af inflammatorisk ledsygdom
US20190112354A1 (en) * 2016-04-22 2019-04-18 Xalud Therapeutics, Inc. Methods and compositions to enhance the anti-inflammatory effects of interleukin 10
UY39298A (es) * 2020-06-26 2022-01-31 Amgen Inc Muteínas de il-10 y proteínas de fusión de las mismas
WO2023114958A1 (en) * 2021-12-16 2023-06-22 Xalud Therapeutics, Inc. Dosing regimen for il-10 encoding expression construct

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6312680B1 (en) 1990-06-29 2001-11-06 Timothy R. Mosmann Methods of treatment using cytokine synthesis inhibitory factor
DK0671933T3 (da) 1992-08-20 1998-09-23 Schering Corp Hidtil ukendte anvendelser af IL-10
US5922018A (en) 1992-12-21 1999-07-13 Artann Corporation Method for using a transrectal probe to mechanically image the prostate gland
US5373317B1 (en) 1993-05-28 2000-11-21 Welch Allyn Inc Control and display section for borescope or endoscope
CA2166118C (en) 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
RU2218348C2 (ru) 1994-07-05 2003-12-10 Стено Рисерч Груп А/С Полипептид с il-10 подобными свойствами (варианты), конъюгат полипептида, фармацевтическая композиция, способ модуляции иммунного ответа у млекопитающего
EP0793504B1 (en) 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US5716804A (en) 1995-04-19 1998-02-10 Schering Corporation Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
US6083919A (en) 1996-12-05 2000-07-04 University Of Florida Materials and methods for treating autoimmune disease
US6201880B1 (en) 1996-12-31 2001-03-13 Electro-Optical Sciences Method and apparatus for electronically imaging a tooth through transillumination by light
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO1999047157A1 (en) 1998-03-17 1999-09-23 Schering Corporation Use of il-10 to treat major depressive disorder
JP2002513775A (ja) 1998-05-06 2002-05-14 トランジェーヌ、ソシエテ、アノニム 細胞の中へのポリヌクレオチドのトランスフェクションを改良する治療組成物を調製するためのヌクレアーゼインヒビターまたはインターロイキン−１０（ｉｌ−１０）の使用、および遺伝子治療に有用な組成物
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6165754A (en) 1999-06-08 2000-12-26 Cornell Research Foundation, Inc. Method of expressing an exogenous nucleic acid
US20050129669A1 (en) 1999-06-21 2005-06-16 Transkaryotic Therapies, Inc., A Massachusetts Corporation DNA construct for effecting homologous recombination and uses thereof
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
WO2002044376A2 (en) 2000-11-28 2002-06-06 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
EP1341522B1 (de) 2000-12-13 2005-11-16 Merckle Gmbh Mikropartikel mit verbessertem freisetzungsprofil und verfahren zu deren herstellung
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
US20030166593A1 (en) 2001-04-30 2003-09-04 Kenneth Chien Non-viral vesicle vector for cardiac specific gene delivery
JP4578735B2 (ja) 2001-08-28 2010-11-10 オリンパス株式会社 内視鏡画像ファイリングシステム
JP2003146909A (ja) 2001-11-07 2003-05-21 Children's Hospital Of Philadelphia 治療用ポリペプチドに対する免疫寛容の誘導
CA2361462A1 (en) 2001-11-07 2003-05-08 Katherine A. High Induction of tolerance to a therapeutic polypeptide
US6967018B2 (en) 2002-01-11 2005-11-22 Applied Genetic Technologies Corporation Adiponectin gene therapy
AU2003221745A1 (en) 2002-04-19 2003-11-03 University Of Florida rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
US20040186357A1 (en) 2002-08-20 2004-09-23 Welch Allyn, Inc. Diagnostic instrument workstation
CA2494772C (en) 2002-08-29 2015-12-01 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US20040142893A1 (en) 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7530946B2 (en) 2003-08-15 2009-05-12 Scimed Life Systems, Inc. Compact endoscope
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
JP2008505104A (ja) 2004-07-01 2008-02-21 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 免疫抑制性エキソソーム
US20060073119A1 (en) 2004-09-01 2006-04-06 Avigen, Inc. Methods for treating neurodegenerative disorders
EP1901769A2 (en) 2005-05-02 2008-03-26 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
EP2816118B1 (en) 2005-05-31 2018-10-17 The Regents of the University of Colorado, a body corporate Methods for delivering genes
DE602006011311D1 (de) * 2005-05-31 2010-02-04 Univ Colorado Il-10 mutante
WO2007016501A2 (en) 2005-08-01 2007-02-08 The University Of Chicago Compositions and method for brain specific targeted delivery of therapeutic agents
US20100196492A1 (en) 2007-03-08 2010-08-05 Green Jordan J Electrostatic coating of particles for drug delivery
US7846428B2 (en) * 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2651407B1 (en) 2010-12-15 2016-12-21 Olatec Industries LLC 3-methanesulfonylpropionitrile for treating inflammation and pain
US20150044281A1 (en) 2012-01-06 2015-02-12 The Regents Of The University Of Colorado, A Body Corporate Methods for the treatment of multiple sclerosis and other demyelinating disorders
DK3369435T3 (da) 2013-07-18 2019-11-25 Xalud Therapeutics Inc Sammensætning til behandling af inflammatorisk ledsygdom
US20190112354A1 (en) 2016-04-22 2019-04-18 Xalud Therapeutics, Inc. Methods and compositions to enhance the anti-inflammatory effects of interleukin 10

Also Published As

Publication number Publication date
EP3021873B1 (en) 2018-09-05
JP2020037562A (ja) 2020-03-12
EP3021873B8 (en) 2018-10-24
US10512672B2 (en) 2019-12-24
EP3369435A1 (en) 2018-09-05
EP3021873A4 (en) 2016-11-30
JP2022031682A (ja) 2022-02-22
HUE046944T2 (hu) 2020-03-30
DK3369435T3 (da) 2019-11-25
ES2700826T3 (es) 2019-02-19
US20220313785A1 (en) 2022-10-06
PT3021873T (pt) 2018-12-10
CY1120946T1 (el) 2019-12-11
US20230158114A1 (en) 2023-05-25
US20200093892A1 (en) 2020-03-26
PL3369435T3 (pl) 2020-04-30
PT3369435T (pt) 2019-12-05
JP2016525522A (ja) 2016-08-25
HRP20192043T1 (hr) 2020-02-07
HUE042463T2 (hu) 2019-07-29
EP3369435B1 (en) 2019-09-04
LT3021873T (lt) 2018-11-26
EP3021873A1 (en) 2016-05-25
RS59735B1 (sr) 2020-02-28
JP7066669B2 (ja) 2022-05-13
HRP20181913T1 (hr) 2019-01-11
WO2015009955A1 (en) 2015-01-22
RS57974B1 (sr) 2019-01-31
DK3021873T3 (en) 2018-12-17
SI3369435T1 (sl) 2020-03-31
ES2760902T3 (es) 2020-05-18
CY1122673T1 (el) 2021-03-12
US20160235816A1 (en) 2016-08-18
PL3021873T3 (pl) 2019-01-31
LT3369435T (lt) 2020-01-10

Similar Documents

Publication Publication Date Title
HK1249507A1 (zh) 用於治療炎性障礙的新化合物及其藥物組合物
IL243976B (en) kdm1a inhibitors for disease treatment
HK1220611A1 (zh) 用於治療胃腸道病症的組成物
HK1222800A1 (zh) 關節護理組合物
EP2990419A4 (en) Preventive or therapeutic agent for inflammatory disease
HRP20181913T1 (hr) Sastav za liječenje upale bolesti zglobova
ZA201604225B (en) Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
HK1221166A1 (zh) 炎症性病症的治療
GB201315079D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314016D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314015D0 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases